Transcranial Magnetic Stimulation System in Neurological Rehabilitation: Harnessing Neuroplasticity for Recovery After Brain Injury

Introduction: A New Era in Neurorehabilitation

Stroke, traumatic brain injury, and neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease often leave patients with devastating motor, cognitive, and functional deficits. Traditional rehabilitation—physical therapy, occupational therapy, and speech therapy—remains the cornerstone of recovery. However, for many patients, spontaneous neurological recovery plateaus within months, leaving residual impairments that profoundly affect quality of life.

Originally developed as a diagnostic tool for cortical excitability, TMS—particularly repetitive TMS (rTMS) —has evolved into a powerful therapeutic modality for neurological rehabilitation. By delivering targeted magnetic pulses to specific brain regions, TMS can modulate cortical excitability, rebalance disrupted interhemispheric communication, and harness the brain's intrinsic capacity for neuroplasticity.

The Scientific Basis: Restoring Interhemispheric Balance

The Interhemispheric Imbalance Model

After a unilateral stroke or brain injury, the normal balance between the two cerebral hemispheres is disrupted. The contralesional (healthy) hemisphere becomes hyperexcitable, exerting excessive inhibitory influence over the ipsilesional (damaged) hemisphere through transcallosal pathways. This maladaptive plasticity impedes recovery.

rTMS addresses this imbalance through frequency-dependent modulation:

· Low-frequency (≤1 Hz) rTMS : Inhibitory—applied to the contralesional hemisphere to reduce excessive transcallosal inhibition 

· High-frequency (≥5 Hz) rTMS : Excitatory—applied to the ipsilesional hemisphere to enhance cortical output 

Clinical Applications in Neurological Conditions

1. Stroke Rehabilitation: Upper Limb Motor Recovery

 Upper limb hemiplegia affects over 80% of acute stroke patients and remains incompletely recovered in more than 40% of chronic cases . TMS has emerged as a leading intervention to address this persistent disability.

2. Parkinson's Disease: Motor and Non-Motor Symptoms

Parkinson's disease (PD) affects motor function through dopamine depletion in the basal ganglia, but its effects extend to gait, posture, and non-motor symptoms like depression and sleep disturbance. rTMS has become an established non-pharmacological treatment adjunct in PD.

Clinical Guidelines: The 2021 Chinese rTMS Treatment Guidelines for Parkinson's Disease (published in Chinese Journal of Nervous and Mental Diseases) provide the following recommendations:

· High-frequency (5-10 Hz) rTMS: Effective for improving bradykinesia and motor symptoms (B-level recommendation)

· Low-frequency (1 Hz) rTMS: Improves posture and gait disturbances, including freezing of gait—independent of dopaminergic medication status (B-level recommendation)

· rTMS : Effective for non-motor symptoms including depression, sleep disorders, and cognitive dysfunction (varying evidence levels)

A 2025 systematic review confirmed that rTMS, when combined with conventional rehabilitation, significantly improves balance and postural stability as measured by the Berg Balance Scale and Activities-Specific Balance Confidence Scale.

3. Acquired Brain Injury (TBI and Stroke)

Approximately 1.5 million people survive acquired brain injury (ABI) annually in the United States, with 30% experiencing chronic deficits. A 2024 review of 22 studies involving 657 ABI patients found that TMS—alone or combined with neurorehabilitation—effectively improved motor function, cognition, neuropsychiatric symptoms, and somatic complaints . The hormesis-based neuroplasticity model suggests that TMS provides a controlled, low-level challenge that stimulates adaptive cellular responses without overwhelming the injured brain .

4. Emerging Applications

· Post-stroke aphasia and dysphagia : TMS targeting language and swallowing networks shows preliminary efficacy (Level C evidence for aphasia). 

· Alzheimer's disease and mild cognitive impairment : rTMS targeting the dorsolateral prefrontal cortex or default-mode network hubs has demonstrated clinically meaningful cognitive benefits in proof-of-concept studies. 

· Chronic pain and spasticity : TMS modulates pain-processing circuits and may reduce spasticity after brain injury. 

Safety and Practical Considerations

rTMS is non-invasive, well-tolerated, and safe when administered according to established protocols. The most common adverse effects are mild transient headache and scalp discomfort. The most serious risk—seizure—is extremely rare (0.01–0.1% incidence) and typically associated with high-frequency protocols in patients with predisposing factors . The 2021 IFCN Safety Guidelines confirm that rTMS carries a very low risk of seizure, especially with LF protocols.

Q&A

Q1: What is Transcranial Magnetic Stimulation System (TMS) in rehabilitation?

TMS is a non-invasive neuromodulation technique that uses magnetic pulses to stimulate targeted brain regions, promoting neuroplasticity and functional recovery after neurological injury.

Q2: How does TMS help stroke patients recover motor function?

TMS restores the balance between brain hemispheres by inhibiting overactive areas or exciting underactive ones. This "rebalancing" enhances cortical plasticity, allowing the damaged hemisphere to reorganize and improve motor output.

Q3: What neurological conditions can TMS treat?

TMS is used for stroke (upper limb hemiplegia, aphasia, dysphagia), Parkinson's disease (motor and non-motor symptoms), traumatic brain injury, Alzheimer's disease, and multiple sclerosis—with varying levels of evidence.

Q4: What is the difference between low-frequency and high-frequency rTMS?

Low-frequency (≤1 Hz) rTMS is inhibitory and is typically applied to the healthy hemisphere to reduce excessive inhibition of the damaged side. High-frequency (≥5 Hz) rTMS is excitatory and applied to the damaged hemisphere to boost cortical output.

Q5: How long does a typical TMS treatment course last?

A standard course is 2–8 weeks, with daily sessions (3–5 times per week), each lasting 15–20 minutes. Accelerated protocols (iTBS) may achieve results in shorter total time.

Q6: Is TMS safe?

Yes. Mild transient headache and scalp discomfort are common. Seizure risk is extremely low (0.01–0.1%), especially with low-frequency protocols and proper screening.

Q7: Can TMS be combined with other rehabilitation therapies?

Yes. Combining TMS with motor imagery training, physical/occupational therapy, robotics, or peripheral nerve stimulation produces synergistic effects, outperforming either intervention alone.

 Q8: Who should NOT use TMS?

Contraindications include metallic implants in the head (except dental fillings), implanted electronic devices (pacemakers, cochlear implants), and a history of seizures or epilepsy .

Q9: How do I know if TMS will work for me?

Pre-treatment assessment with motor-evoked potentials (MEPs) or functional MRI can help determine target engagement and predict responsiveness. Individualization is key—what works for one patient may not work for another .

Conclusion

Transcranial Magnetic Stimulation System represents a paradigm shift in neurological rehabilitation. By directly modulating the neural circuits that drive motor and cognitive function, TMS offers a mechanism-driven, non-invasive, and safe approach to conditions that have long challenged clinicians.